Drug General Information (ID: DDI170GED4)
  Drug Name Edrophonium Drug Info Alectinib Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antidotes Multikinase Inhibitors
  Structure

 Mechanism of Edrophonium-Alectinib Interaction (Severity Level: Moderate)
     Increased risk of bradycardia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Edrophonium Alectinib
      Mechanism Bradycardia Bradycardia
      Key Mechanism Factor 1
Factor Name Bradycardia
Factor Description Bradycardia is a slow heart rate in which the heart beats less than 60 times per minute. If the heart rate is very slow and the heart is not pumping enough oxygen-rich blood to the body, and you may feel dizzy, very tired or weak, and short of breath.
      Mechanism Description
  • Increased risk of bradycardia by the combination of Edrophonium and Alectinib 

Recommended Action
      Management Caution is advised when alectinib is prescribed with other drugs that can cause bradycardia (e.g., beta-blockers calcium channel blockers digitalis dolasetron flecainide ivabradine lacosamide mefloquine moricizine propafenone quinine succinylcholine sunitinib thalidomide anticholinesterase or cholinergic agents protease inhibitors such as atazanavir, lopinavir/ritonavir, and saquinavir/ritonavir). Heart rate and blood pressure should be monitored regularly, and patients should be counseled to seek medical attention if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.

References
1 Product Information. Kaletra (lopinavir-ritonavir) Abbott Pharmaceutical, Abbott Park, IL.
2 Product Information. Alecensa (alectinib). Genentech, South San Francisco, CA.